| __timestamp | ImmunityBio, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4326000 | 59644696 |
| Thursday, January 1, 2015 | 226206000 | 79541000 |
| Friday, January 1, 2016 | 94391000 | 98015000 |
| Sunday, January 1, 2017 | 53821000 | 103958000 |
| Monday, January 1, 2018 | 35463000 | 103654000 |
| Tuesday, January 1, 2019 | 46456000 | 128951000 |
| Wednesday, January 1, 2020 | 71318000 | 135799000 |
| Friday, January 1, 2021 | 135256000 | 149883000 |
| Saturday, January 1, 2022 | 102708000 | 220206000 |
| Sunday, January 1, 2023 | 129620000 | 265542000 |
Igniting the spark of knowledge
In the ever-evolving landscape of biotechnology, understanding the financial dynamics of companies is crucial. Over the past decade, ImmunityBio, Inc. and Travere Therapeutics, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, ImmunityBio's SG&A expenses surged by approximately 2,900%, peaking in 2015 and 2021. In contrast, Travere Therapeutics exhibited a steadier growth, with a 345% increase, reaching its zenith in 2023. This divergence highlights ImmunityBio's aggressive expansion strategies, while Travere's consistent rise suggests a more measured approach. As these companies navigate the competitive biotech sector, their financial strategies offer valuable insights into their operational priorities and market positioning. Understanding these trends is essential for investors and stakeholders aiming to make informed decisions in this dynamic industry.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and ImmunityBio, Inc.
Genmab A/S vs Travere Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and ImmunityBio, Inc.
Comparing SG&A Expenses: Catalent, Inc. vs ImmunityBio, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Alpine Immune Sciences, Inc. or Travere Therapeutics, Inc.
Amneal Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Travere Therapeutics, Inc.
Comparing SG&A Expenses: ImmunityBio, Inc. vs MannKind Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and Taro Pharmaceutical Industries Ltd.
Operational Costs Compared: SG&A Analysis of Protagonist Therapeutics, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ligand Pharmaceuticals Incorporated vs Travere Therapeutics, Inc.
Comparing SG&A Expenses: Agios Pharmaceuticals, Inc. vs Travere Therapeutics, Inc. Trends and Insights